Summary & Overview
CPT 90682: Quadrivalent Recombinant Influenza Vaccine, IM
CPT code 90682 denotes a quadrivalent influenza vaccine delivered by intramuscular injection and manufactured through recombinant DNA technology. As a preservative- and antibiotic-free protein-based influenza vaccine, it is an important option in seasonal immunization programs and for patients with specific vaccine component considerations. Nationally, this vaccine code is relevant across public and private payers for preventive care and population health efforts.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, billing and service characteristics, common modifiers, and expected sites of service. The publication also outlines payer coverage patterns, benchmarking metrics where available, and recent policy or coding guidance affecting vaccine administration claims. Practical information on documentation elements and coding conventions is provided to support accurate submission and claim adjudication.
Data not available in the input for ICD-10 diagnoses, associated taxonomies, and detailed payer-specific fee benchmarks.
Billing Code Overview
CPT code 90682 represents a quadrivalent influenza vaccine administered intramuscularly. The vaccine is produced using recombinant DNA technology, contains only a viral protein, and does not include preservatives or antibiotics.
-
Service type: Vaccine administration (intramuscular injection)
-
Typical site of service: Outpatient clinics, physician offices, pharmacies, and other ambulatory care settings where routine immunizations are provided.
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult presents to an outpatient primary care clinic during influenza season requesting routine immunization. The clinician documents a review of allergy history (no egg allergy requiring precautions), verifies prior influenza vaccinations, and confirms indication for quadrivalent recombinant influenza vaccine. The vaccine described by 90682 is administered intramuscularly into the deltoid muscle. The clinical workflow includes patient identification and consent, screening for contraindications (e.g., severe allergic reaction to a prior dose), preparation of the preservative-free recombinant protein vaccine, intramuscular injection, observation for 15 minutes for immediate adverse reactions, documentation of lot number and site in the medical record, and billing using 90682 with any applicable modifier(s) and the appropriate ICD-10 diagnosis code reflecting routine vaccination or encounter reason.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/Not used for reporting additional information | Rarely used on professional claims; present in list but no specific CMS definition for outpatient vaccine usage |